Lung cancer in non-smokers is a well recognised entity. Lung cancer in non-smokers is wholly associated with adenocarcinoma or variants thereof. A number of somatic molecular aberrations are observed in lung cancer recently, which has lead to various tailored treatment options based on clinical, molecular and genetic factors. TKI is an important option of treatment in lung cancer which has a role in the first-, second- and third-line management in selected group of lung cancer patients.